Nammi Therapeutics, Inc.

4 articles about Nammi Therapeutics, Inc.

• Amgen and Biolabs LA at the Lundquist Institute Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket

  1/6/2023

  Amgen and BioLabs LA at The Lundquist Institute announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California.

• Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer

  6/16/2022

  Nammi Therapeutics, Inc., a Los Angeles based immunotherapy company, announced that the US Food and Drug Administration has granted orphan drug designation to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.

• Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma

  6/13/2022

  Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma.

• Nammi Therapeutics Unveils Two Novel Immunotherapies at AACR Conference

  4/9/2021

  Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announces its first two cancer drug candidates, one from each of Nammi's distinctive drug development platforms, Nammisomes and Masked ImmunoCytokines (MIC).